Brain Cancer Articles

Oncolytic Virus Therapy Passes Early Efficacy Tests in Glioma Subtypes
A2-step oncolytic virus has demonstrated promising signals against aggressive forms of brain cancers, including recurrent glioblastoma multiforme and anaplastic astrocytoma, in early clinical studies.
The FDA has granted bevacizumab a full approval for the treatment of adult patients with glioblastoma that progressed following prior therapy.
Immunotherapy Combinations Offer Hope in Glioblastoma
Immunotherapy has shown promise for treatment of glioblastoma multiforme (GBM), the most common primary brain tumor in adults with historically poor prognosis, but experts agree that combination regimens have the greatest potential to achieve durable response.
The FDA approved the first biosimilar for the treatment of cancer. ABP-215 (bevacizumab-awwb; Mvasi), a biosimilar for bevacizumab (Avastin), is indicated for the treatment of colorectal, lung, brain, kidney, and cervical cancers in adult patients.
Glioblastoma Platform Trial Investigating Multiple Drugs in Parallel
In an ongoing phase II trial, researchers are investigating several targeted agents for use in the treatment of patients with glioblastoma (GBM).
ODAC Unanimously Supports Bevacizumab Biosimilar ABP-215
The FDA’s Oncologic Drugs Advisory Committee voted 17-0 to recommend approval for ABP-215, a biosimilar for bevacizumab (Avastin) to treat a range of solid tumors.
Investigators are seeking to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide will improve the survival of patients with newly diagnosed glioblastoma multiforme with EGFR amplification.
Tumor treating fields reduced the risk of death by 37% and overall survival was extended by a median of 5 months for patients with glioblastoma multiforme, in a landmark analysis of the EF-14 trial.
Patient-Derived Cancer Stem Cells Offer Diagnostic and Therapeutic Potential in Brain Cancer
A brain tumor research group at the UW Carbone Cancer Center focuses on biological studies of patient-derived glioblastoma multiforme (GBM) cancer stem cells, combined with analysis of patient-matched serum-cultured GBM and an annotated GBM tissue microarray, to identify clinically relevant biomarkers.
In neuro-oncology, newfound interest has sparked investigations into metabolic pathways in tumors with the hope of identifying novel therapeutic targets.
Publication Bottom Border
Border Publication